LakeShore Biopharma

About:

LakeShore Biopharma is a global medical company that develops and manufactures human used vaccines and immune products..

Website: https://en.lakeshorebio.com/

Twitter/X: YSBiopharma

Top Investors: OrbiMed, F-Prime Capital, Hillhouse Investment, Eight Roads Ventures, Adjuvant Capital

Description:

LakeShore Biopharma is a global, fully integrated medical company engaged in discovering, developing and commercializing innovative biotherapeutics for cancers and infectious diseases using our novel PIKA® immunomodulating technology. PIKA technology augments both innate and adaptive immune responses through the TLR3, RIG-I and MDA5 pathways. Products in clinical development include YS-ON-001 for the treatment of advanced solid tumors, YS-HBV-001 hepatitis B vaccine and the PIKA rabies vaccine for accelerated protection against rabies infection.

Total Funding Amount:

$211M

Estimated Revenue Range:

$100M to $500M

Headquarters Location:

Hong Kong, Hong Kong Island, Hong Kong

Founded Date:

2002-01-01

Contact Email:

lakes_hongkong(AT)lakeshorebio.com

Founders:

Yi Zhang

Number of Employees:

501-1000

Last Funding Date:

2024-02-09

IPO Status:

Public

Industries:

© 2025 bioDAO.ai